» Articles » PMID: 12824889

HCDC4b, a Regulator of Cyclin E, As a Direct Transcriptional Target of P53

Overview
Journal Cancer Sci
Specialty Oncology
Date 2003 Jun 26
PMID 12824889
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

To identify p53-target genes we have been using a cDNA-microarray system to assess gene expression in a p53-mutated glioblastoma cell line (U373MG) after adenovirus-mediated transfer of wild-type p53 into the p53-deficient cells. In the work reported here, expression of hCDC4b, which encodes one of the four subunits of the SCF (ubiquitin ligase) complex responsible for degradation of cyclin E, was dramatically up-regulated by infection with Ad-p53. An electrophoretic mobility-shift assay and a chromatin immunoprecipitation assay indicated that a potential p53-binding site (p53BS) present in exon 1b of the hCDC4 gene was able to bind to p53, and a reporter assay confirmed that this p53BS had p53-dependent transcriptional activity. Expression of endogenous hCDC4b, but not the alternative transcript of this gene, hCDC4a, was induced in a p53-dependent manner in response to genotoxic stresses caused by UV irradiation and adriamycin treatment, suggesting that each transcript has a different functional role. These results suggest that hCDC4b is a previously unrecognized transcriptional target of the p53 protein, and that by negatively regulating cyclin E through induction of hCDC4b, p53 might stop cell-cycle progression at G0-G1. This would represent a novel mechanism for p53-dependent control of the cell cycle, in addition to the well-known p21(WAF1) machinery.

Citing Articles

Combinatorial mapping of E3 ubiquitin ligases to their target substrates.

Suiter C, Calderon D, Lee D, Chiu M, Jain S, Chardon F Mol Cell. 2025; 85(4):829-842.e6.

PMID: 39919746 PMC: 11845296. DOI: 10.1016/j.molcel.2025.01.016.


Isoform alterations in the ubiquitination machinery impacting gastrointestinal malignancies.

Kasturirangan S, Nancarrow D, Shah A, Lagisetty K, Lawrence T, Beer D Cell Death Dis. 2024; 15(3):194.

PMID: 38453895 PMC: 10920915. DOI: 10.1038/s41419-024-06575-z.


FBXW7 in breast cancer: mechanism of action and therapeutic potential.

Chen S, Leng P, Guo J, Zhou H J Exp Clin Cancer Res. 2023; 42(1):226.

PMID: 37658431 PMC: 10474666. DOI: 10.1186/s13046-023-02767-1.


Inhibitors Targeting the F-BOX Proteins.

Naseem Y, Zhang C, Zhou X, Dong J, Xie J, Zhang H Cell Biochem Biophys. 2023; 81(4):577-597.

PMID: 37624574 DOI: 10.1007/s12013-023-01160-1.


The Role of FBXW7 in Gynecologic Malignancies.

Di Fiore R, Suleiman S, Drago-Ferrante R, Subbannayya Y, Suleiman S, Vasileva-Slaveva M Cells. 2023; 12(10).

PMID: 37408248 PMC: 10216672. DOI: 10.3390/cells12101415.


References
1.
Spruck C, Strohmaier H, Sangfelt O, Muller H, Hubalek M, Muller-Holzner E . hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002; 62(16):4535-9. View

2.
Hunter T, Pines J . Cyclins and cancer. Cell. 1991; 66(6):1071-4. DOI: 10.1016/0092-8674(91)90028-w. View

3.
Lew D, Dulic V, Reed S . Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell. 1991; 66(6):1197-206. DOI: 10.1016/0092-8674(91)90042-w. View

4.
Strohmaier H, Spruck C, Kaiser P, Won K, Sangfelt O, Reed S . Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 2001; 413(6853):316-22. DOI: 10.1038/35095076. View

5.
Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K . A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000; 404(6773):42-9. DOI: 10.1038/35003506. View